Successful eradication of acquired factor-VIII inhibitor using single low-dose rituximab
With great interest we read the recent recommendations regarding the treatment of acquired hemophilia A published in Haematologica 1 and followed the subsequent discussion.
2, 3 The described treatment algorithm for this disease, which occurs at an incidence of 1.5/million/year, 4 stresses the importance of early eradication of the acquired fVIII-inhibitor. Using prednisolone alone or in combination with cyclophosphamide, this approach will be successful in 30-50% of affected individuals.
5 As Huth-Kühne pointed out, the CD20-antibody rituximab may be an attractive alternative in nonresponders or patients with contraindications to steroids. 6 However, concerns have been raised because of rituximab side-effects including associations with progressive multifocal leukencephalopathy (PML). Furthermore, as Mannucci et al. 2 emphasized, the use of this drug is hampered by its substantial costs. Restricting the administered dose to the lowest effective level, seems to be a reasonable strategy to minimize potential risks and costs of rituximab treatment.
We report a 66-year old male AHA-patient successfully treated with single low-dose rituximab. The patient presented with multiple hematomas and severe anemia after recovering from a respiratory infection. Prolonged activated partial-thromboplastin-time (aPTT) in combination with undetectable fVIII-activity due to a fVIIIinhibitor was observed. History did neither reveal any prior hemorrhages nor a family history of bleeding. Clinical and imaging examinations could not reveal any pathological findings suggesting an idiopathic cause of AHA. Prednisolone (1 mg/kg) was started immediately and 2 units of packed red blood cells had to be administered. Afterwards, bleeding ceased correlating with an increase of fVIII-activity to 28%. Steroids were completely tapered over the next weeks and the patient was lost to follow-up. However, during the following year the patient experienced recurrent episodes of minor bleeding.
Seventeen months after the first onset of AHA, he again presented at our institution for follow-up reporting of no spontaneous bleeding episodes, however with a fVIII-activity of 15% translating into a fVIII-inhibitor of 133 BU (Bethesda units). Another two months later, severe limb-bleeding requiring surgical treatment occurred after a minor accident. FVIII-inhibitor could still be detected at high levels (79 BU). Because of impaired wound-healing, steroids were deemed contraindicated.
Therefore, inhibitor-eradication treatment was started with a single flat dose of 100 mg rituximab given our experiences in patients with auto-immune diseases other than AHA.
8 Treatment was well tolerated and three weeks later complete B-cell depletion could be demonstrated (Figure 1 ). Significant bleeding did not reoccur and even an accident was tolerated without complications. At last presentation, nearly 10 months after rituximab-treatment, the patient had only a low residual fVIII-inhibitor activity, in spite of a normal Bcells count. FVIII-levels stabilized at a level of 15 to 20 % and aPTT was never found to be prolonged again after rituximab treatment
The clinical course of our patient demonstrates that complete B-cell depletion can be achieved with lowdose rituximab in AHA. We are aware that given the persistently low fVIII-level our patient does not meet the strict criteria for inhibitor eradication proposed by Huth-Kühne. On the other hand we have to acknowledge, that he experienced no further bleeding and had inhibitor-titers near the detection limit. We therefore believe that future clinical trials should incorporate this low-dose regimen rather than the classical lymphomadose (e.g. 375 mg/m 2 ) in the treatment of both acquired hemophilia A.
Martin Wermke, 1 Malte von Bonin, 1 Siegmund Gehrisch, Figure 1 . Clinical course overview. Time since diagnosis is given on the x-axis in months. Left y-axis shows fVIII-inhibitor titer in Bethesda-Units (BU), while B-cell-proportion is depicted in percent on the right y-axis. R corresponds to the time of rituximab application.
